Development of a luciferase reporter Jurkat cell line under the control of endogenous interleukin-2 promoter

Abraham, 2004, Jurkat T cells and development of the T-cell receptor signaling paradigm, Nat. Rev. Immunol., 4, 301, 10.1038/nri1330

Angel, 1987, Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans‑acting factor, Cell, 49, 729, 10.1016/0092-8674(87)90611-8

Chrisann, 2016, Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges, Immunotherapy, 8, 821, 10.2217/imt-2016-0002

Chu, 2015, Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells, Nat. Biotechnol., 33, 543, 10.1038/nbt.3198

Durand, 1988, Characterization of antigen receptor response elements within the interleukin-2 enhancer, Mol. Cell. Biol., 8, 1715, 10.1128/MCB.8.4.1715

Fraser, 1991, Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28, Science, 251, 313, 10.1126/science.1846244

Grailer, 2016, 76, 4878

Granelli-Piperno, 1991, Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells, J. Immunol., 147, 2734, 10.4049/jimmunol.147.8.2734

Hanabuchi, 2006, Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL), Blood, 107, 3617, 10.1182/blood-2005-08-3419

Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011

Huse, 2009, The T-cell-receptor signaling network, J. Cell Sci., 122, 1269, 10.1242/jcs.042762

Jutz, 2016, Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: simultaneous measurement of NF-κB, NFAT and AP-1, J. Immunol. Methods, 430, 10, 10.1016/j.jim.2016.01.007

Kamps, 1990, The promoter of the human interleukin-2 gene contains two octamer-binding sites and is partially activated by the expression of Oct-2, Mol. Cell. Biol., 10, 5464, 10.1128/MCB.10.10.5464

Kouranova, 2016, CRISPRs for optimal targeting: delivery of CRISPR components as DNA, RNA, and protein into cultured cells and single-cell embryos, Hum. Gene Ther., 27, 464, 10.1089/hum.2016.009

Lee, 1987, Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements, Cell, 49, 741, 10.1016/0092-8674(87)90612-X

Leyland, 2017, A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy, which is further enhanced in combination with an OX40 agonist, Clin. Cancer Res., 10.1158/1078-0432.CCR-16-2000

Mellman, 2011, Cancer immunotherapy comes of age, Nature, 480, 480, 10.1038/nature10673

Michelini, 2010, Cell-based assays: fuelling drug discovery, Anal. Bioanal. Chem., 398, 227, 10.1007/s00216-010-3933-z

Nocentini, 2005, GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily, Eur. J. Immunol., 35, 1016, 10.1002/eji.200425818

Nocentini, 1997, A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis, Proc. Natl. Acad. Sci. U. S. A., 94, 6216, 10.1073/pnas.94.12.6216

Ohtsuka, 1996, Analysis of the T-cell activation signaling pathway mediated by tyrosine kinases, protein kinase C, and Ras protein, which is modulated by intracellular cyclic AMP, Biochim. Biophys. Acta, 1310, 223, 10.1016/0167-4889(95)00172-7

Parra, 1995, Costimulation of human CD4+ T cells with LFA-3 and B7 induce distinct effects on AP-1 and NF-kappa B transcription factors, J. Immunol., 155, 1132, 10.4049/jimmunol.155.3.1132

Pawelec, 1982, Constitutive interleukin 2 production by the JURKAT human leukemic T cell line, Eur. J. Immunol., 12, 387, 10.1002/eji.1830120506

Rizvi, 2015, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol., 16, 257, 10.1016/S1470-2045(15)70054-9

Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082

Robert, 2015, Pembrolizumab versus Ipilimumab in Advanced Melanoma, N. Engl. J. Med., 372, 2521, 10.1056/NEJMoa1503093

Ronchetti, 2004, GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations, Eur. J. Immunol., 34, 613, 10.1002/eji.200324804

Schneider, 1977, Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma, Int. J. Cancer, 19, 621, 10.1002/ijc.2910190505

Sen, 1986, Multiple nuclear factors interact with the immunoglobulin enhancer sequences, Cell, 46, 705, 10.1016/0092-8674(86)90346-6

Shaw, 1988, Identification of a putative regulator of early T cell activation genes, Science, 241, 202, 10.1126/science.3260404

Shimizu, 2002, Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance, Nat. Immunol., 3, 135, 10.1038/ni759

Tone, 2003, Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells, Proc. Natl. Acad. Sci. U. S. A., 100, 15059, 10.1073/pnas.2334901100

Vilgelm, 2016, Combinatorial approach to cancer immunotherapy: strength in numbers, J. Leukoc. Biol., 100, 275, 10.1189/jlb.5RI0116-013RR

Weiss, 1984, The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level, J. Immunol., 133, 123, 10.4049/jimmunol.133.1.123